Copenhagen, Feb 25, 2026, 13:46 CET — Regular session
- Novo Nordisk shares edged lower in Copenhagen as investors weighed fresh clues on pricing and the company’s drug pipeline.
- Starting Jan. 1, 2027, the company will lower U.S. list prices for Wegovy and Ozempic.
- Analysts say competition with Eli Lilly in the obesity-drug space is heating up, and pricing pressures are mounting.
Novo Nordisk (NOVOb.CO) slipped roughly 1.7% to 239.5 Danish crowns on Wednesday. The shares continued to feel pressure after new U.S. pricing steps and lingering doubts about its upcoming obesity drug. (Hl)
This swing is significant. Novo’s bullish story has depended on two pieces: Wegovy growth staying on track, and the successful launch of a next-gen drug without getting sucked into a price fight with Eli Lilly. Both now seem less certain after developments in recent days.
It’s been a steep slide. Novo has lost about $475 billion in market cap since peaking in June, wiping out what Reuters calls the remaining gains from the Wegovy boom. (Reuters)
The company announced Tuesday it plans to slash U.S. list prices for Wegovy by roughly 50%, and for Ozempic by as much as 35%, starting Jan. 1, 2027. The cuts are meant to match lower Medicare prices required under the Inflation Reduction Act. Novo executive Jamey Millar described the decision as an effort to provide “lower list prices” and help reduce out-of-pocket spending. Bernstein’s Courtney Breen, for her part, said this isn’t “the beginning of a price war.” (Reuters)
Pipeline jitters persist. “We struggle to identify a reason why a patient would be prescribed CagriSema vs. tirzepatide,” BMO Capital Markets’ Evan David Seigerman wrote, following fresh head-to-head results from Novo that put its next-gen candidate behind Lilly’s Zepbound. (Reuters)
Banks are finally quantifying the hit. Barclays slashed its peak sales estimate for CagriSema, dropping the figure to $2 billion—down sharply from $12 billion. The bank called out just how significant the setback is for Novo as it battles Lilly; Novo still aims for a launch next year, assuming the U.S. FDA signs off by the end of 2026. (Reuters)
Novo put some of the spotlight on its broader obesity pipeline. Alongside United Laboratories, the company reported that a mid-stage China trial of their “triple G” candidate, UBT251, delivered up to 19.7% mean weight loss over 24 weeks. Chief scientific officer Martin Holst Lange called the results “very encouraged.” (Reuters)
Even so, the immediate question is blunt: unless Novo decisively outperforms Lilly on either efficacy or tolerability, expectations are set for the rivalry to shift into a battle over access, supply, and price—territory where margins usually get squeezed.
There’s also a risk it backfires. Should the lower list prices fall short in attracting new patients—or if insurers seize the opportunity to push for steeper rebates—the change could simply erode margins, with no lift in volume. Any fresh trial setback would only harden the market’s stance.
Coming up, investors will be watching for what management says about pricing and developments in the obesity pipeline at the annual general meeting set for March 26. First-quarter numbers arrive May 6. (Novonordisk)
